Majid Al Othman

Head of Radiation Oncology at Johns Hopkins Aramco Healthcare

[Majid Al Othman @othmanmo]

Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline https://t.co/dET7uQ3qfZ

[Drew Moghanaki @DrewMoghanaki]

One of the joys with giving International lectures is learning what questions the audience is curious about. It helps me appreciate how advanced our technologies are around the world, and provides an opportunity to be stumped to inspire a new learning opportunity. Both happened today! 🇸🇦

[Majid Al Othman @othmanmo]

Upcoming quarterly webinars in the series.

[Majid Al Othman @othmanmo]

Recording of the 1st quarterly SIOP/PROS webinar in the series on pediatric radiation therapy. In the comments is the schedule for the upcoming site-specific webinars.
https://t.co/s0hG4d67uG

[Majid Al Othman @othmanmo]

Latest ASTRO journal podcast discussing an important consensus statement in cardio-oncology and its practical implications with the authors, hosted by yours truly.
https://t.co/wZN8BDDHLl

[Majid Al Othman @othmanmo]

WCLS 2023: IMRT Reduces Pulmonary Toxicity, Radiation Exposure to the Heart Versus 3D-CRT in Patients With NSCLC | PracticeUpdate https://t.co/zM9cA8HRpX

[FranziskaHausmann @FranziskaHauth]

Amazing talk by Maria van Rijn-Dekker at #ESTRO2023 on Adaption of treatment planning to reduce xerostomia in patients with head and neck carcinoma- such an important topic for quality of life! thanks especially for the 'how-to' Information

[Dr XY Jiang (Xj) @RadmadMedic1998]

“ RCT is not reality. It is a modelling of the reality. … selection is the Key! …guideline is a surrogate of evidence… only as good as the evidence reviewed. 👍presidential symposium-“ the Evidence gap” #ESTRO2023

[Zuzanna Nowicka @zuzannows]

Brilliant lecture from @SorenBentzen during the Presidential symposium at #ESTRO2023, highlighting the need for randomized evidence in radiotherapy. 'Guidelines are not evidence-based, they are a surrogate for evidence'

[Michael Chuong @MikeChuongMD]

Masterful presidential session talk (as always!) by the amazing @SorenBentzen about the need for high quality evidence-based medicine and a word of caution that randomized trial data should be critically assessed and not always taken at face value #ESTRO2023

[AIRO Head and Neck Cancer Group @AiroHead_Neck]

Hans Langendijk at #ESTRO2023 on Comprehensive Toxicity Profile:
- Personalized approach to optimize dose distribution in HNC pts
- Reduction of severe acute and late toxicities
- Potential estimate of the benefits of PBT
- Oral cavity as the most important OAR in HN RT

[Theresa O Donovan @odonovmt]

Balermpas: ongoing #ART trials with varied endpoints. What are our actual goals of #ART? Who will benefit? #ESTRO23 #ESTRO2023

[Alison Tree 💙 @alison_tree]

Fantastic talk by @SahgalArjun on potential for patient benefit from MRI-guided adaptive RT in GBM. Could methylation status predict who benefits most? #ESTRO2023

[Joanna Javor @JoannaJavor]

Do we need to reduce PTV to spare OARs? 2nd analysis of COMET 5 ph 2 trial.
36% PTVs under covered.
Under coverage did not predict worse LR control of PFS.
GTV likely still received full dose & systemic therapy may contribute to this.
So yes- safety first !#ESTRO2023

[Shankar Siva @_ShankarSiva]

#ESTRO2023- 50 mo follow up from DESTROY fractionation trial from Carole Mercier. Basket histo study of lymph and bone targets. mPFS lower for 5 fx SABR group (?But mostly distant failure, so unclear attribution). Nice to see the conclusion that single fraction 🥊is preferred!

[Ane Appelt @cancerphysicist]

It’s always brilliant to see the STAR-TREC phase II data - here expertly presented by Prof Marijnen. Phase III is recruiting very well - with >210 pts randomised in 3 countries to the organ preservation arms #ESTRO2023 #rectalcancer #organpreservation

[Shankar Siva @_ShankarSiva]

Dr Stephanie Kroeze presents a Delphi consensus of combination systemic therapy and SRS/SABR. ➡️Consensus to interrupt with targeted therapy
➡️large body of evidence with checkpoint blockade (ICI)
➡️ but why interrupt ICI for a week? Half-life of many, many weeks… 🧐 #ESTRO2023

[Prof Suneil Jain @DrSuneil_PCa]

@DrAndrewLoblaw presents a fantastic Overview of dose escalation in prostate cancer and highlights the extremely important ASCENDE SBRT study which will open later this year.

[Majid Al Othman @othmanmo]

ESTRO ACROP GUIDELINE on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer - ScienceDirect https://t.co/lzD8nnSneF

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

HDR brachytherapy as monotherapy: